Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for prevention of chronic migraine in adolescents
2020-001009-22Phase 3Active
- Sponsor
- Lundbeck
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Eptinezumab IV with Placebo IV (2 arms). Primary endpoint: Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1–12. Started Apr 2022; status: active.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2020-001009-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001009-22.